Duchenne News

September 21, 2023
Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
August 30, 2023
FibroGen announces topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne.
August 7, 2023
Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
July 21, 2023
PepGen shares their 2023 Q2 newsletter
July 5, 2023
Italfarmaco announces that the FDA has completed filing review and accepted the company’s NDA for Givinostat.
June 27, 2023
Edgewise Therapeutics announces positive 12-month topline results from the ongoing ARCH study for Becker muscular dystrophy
June 22, 2023
Sarepta announces U.S. Food and Drug Administration accelerated approval of ELEVIDYS.
June 20, 2023
Santhera announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals.
June 8, 2023
Sarepta shares enrollment updates for SRP-9001-303 study.
June 8, 2023
Antisense Therapeutics announces that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne.

Experience the magic of camp promise

Complete applications due April 3, 2023.